AbbVie Reports Second|Quarter 2020 Financial Results
AbbVie Reports Third-Quarter 2020 Financial Results
AbbVie Reports Third-Quarter 2020 Financial Results. • Reports Third-Quarter Diluted EPS of $1.29 on a GAAP Basis; Adjusted Diluted EPS of $2.83.
Press Release | AbbVie Investor Relations
AbbVie Reports Third-Quarter 2017 Financial Results. • Reports Third-Quarter ... 2020. For 2018, AbbVie expects adjusted EPS in the range of $6.37 to ...
November 14, 2024 - AbbVie News Center
All news ; October 30, 2024. AbbVie Reports Third-Quarter 2024 Financial Results ; October 01, 2024. AbbVie to Host Third-Quarter 2024 Earnings Conference Call.
press release - Abbvie Investor Relations
... financial results for the second quarter ended June 30, 2016. “AbbVie ... 1. Specified items impacted results as follows: 6M16. Earnings, Diluted. As reported ...
May 01, 2020. ImmunoGen Reports Recent Progress and First Quarter 2020 Financial Results. May 01, 2020. AbbVie Reports First-Quarter 2020 Financial Results. - ...
AbbVie Reports Third-Quarter 2021 Financial Results
Global net revenues from the immunology portfolio were $6.674 billion , an increase of 15.3 percent on a reported basis, or 14.9 percent on an ...
SEC filings - Abbvie Investor Relations
SEC Filing Keyword Search ; 11/04/24, 10-Q · Quarterly report which provides a continuing view of a company's financial position. Quarterly ...
ImmunoGen Reports Recent Progress and 2020 Financial Results
Total revenues in the fourth quarter and year ended December 31, 2020 increased to $85.8 million and $132.3 million , respectively, compared to ...
AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
Financial results for 2021 and 2020 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with ...
October 30, 2024. AbbVie Reports Third-Quarter 2024 Financial Results. October 29, 2024. SkinSpirit joins Allergan Aesthetics in Supporting Girls Inc. and ...
AbbVie Reports Third-Quarter 2024 Financial Results ... November 16, 2020. Cerevel Therapeutics Announces Third Quarter 2020 Financial Results and Key Business ...
November 12, 2020. AbbVie to Present at the Wolfe Research Healthcare Conference. October 30, 2020. AbbVie Reports Third-Quarter 2020 Financial Results. - ...
The Investor Relations website contains information about AbbVie's business for stockholders, potential investors, and financial analysts.
AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results
AbbVie is issuing its standalone GAAP diluted EPS guidance for the full-year 2020 of $7.66 to $7.76, representing growth of 46.0 percent at the midpoint.
AbbVie: Pharmaceutical Research & Development
Our focus and capabilities address tough challenges that lead to improved lives. Quarterly Earnings. AbbVie Reports Third-Quarter 2024 Financial Results.
ImmunoGen Reports Recent Progress and Third Quarter 2021 ...
Revenues for the quarter ended September 30, 2021 were $9.2 million , compared with $18.2 million for the quarter ended September 30, 2020 .
ImmunoGen Reports Recent Progress and 2021 Financial Results
$49.0 million for the quarter ended December 31, 2021 compared to · $39.6 million for the quarter ended December 31, 2020 , and · $151.1 million ...
AbbVie Reports Second-Quarter 2014 Financial Results
Adjusted selling, general and administrative (SG&A) expense was 27.1 percent of sales in the second quarter, reflecting continued investment in our growth ...
AbbVie Reports Third-Quarter 2015 Financial Results - Oct 30, 2015
The adjusted operating margin in the third quarter was 44.9 percent, compared to 38.5 percent in third-quarter 2014. On a GAAP basis, the ...
AbbVie Reports Third-Quarter 2015 Financial Results
Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were $1.13 in the third quarter, up nearly 27 ...